MS patients on ozanimod: how long does treatment last?
NCT ID NCT05811416
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows about 200 people with relapsing-remitting multiple sclerosis (RRMS) who are starting ozanimod (Zeposia®) for the first time. Researchers want to see how long patients continue the medication in everyday practice and how well it controls their disease. The study does not test a new drug—it simply observes real-world use and outcomes over 24 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Institution - 0001
Barcelona, 08008, Spain